Janux Therapeutics, Inc. – NASDAQ:JANX
Janux Therapeutics stock price today
$24.69
-29.41
-54.36%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Janux Therapeutics stock price monthly change
+22.32%
month
Janux Therapeutics stock price quarterly change
+22.32%
quarter
Janux Therapeutics stock price yearly change
+397.70%
year
Janux Therapeutics key metrics
Market Cap | 3.21B |
Enterprise value | 552.31M |
P/E | -8.33 |
EV/Sales | 64.13 |
EV/EBITDA | -9.49 |
Price/Sales | 67.16 |
Price/Book | 1.80 |
PEG ratio | 0.89 |
EPS | -1.22 |
Revenue | 7.28M |
EBITDA | -71.32M |
Income | -55.59M |
Revenue Q/Q | -38.86% |
Revenue Y/Y | -19.66% |
Profit margin | -732.22% |
Oper. margin | -779.04% |
Gross margin | 0% |
EBIT margin | -779.04% |
EBITDA margin | -978.8% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeJanux Therapeutics stock price history
Janux Therapeutics stock forecast
Janux Therapeutics financial statements
Average Price Target
$70.25
Potential upside: 184.52%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.05M | -17.50M | -1656.39% |
|---|---|---|---|
| Sep 2023 | 2.51M | -11.56M | -459.59% |
| Dec 2023 | 2.46M | -11.75M | -477.77% |
| Mar 2024 | 1.25M | -14.76M | -1178.91% |
| 2024-03-08 | -0.37 | -0.25 |
|---|---|---|
| 2024-05-07 | -0.35 | -0.3 |
| Jun 2023 | 341500000 | 42.03M | 12.31% |
|---|---|---|---|
| Sep 2023 | 386850000 | 37.90M | 9.8% |
| Dec 2023 | 380407000 | 36.05M | 9.48% |
| Mar 2024 | 688984000 | 33.22M | 4.82% |
| Jun 2023 | -15.05M | 17.87M | 528K |
|---|---|---|---|
| Sep 2023 | -11.70M | -61.45M | 56.60M |
| Dec 2023 | -9.90M | 11.12M | 831K |
| Mar 2024 | -14.83M | -113.73M | 322.17M |
Janux Therapeutics alternative data
| Aug 2023 | 62 |
|---|---|
| Sep 2023 | 67 |
| Oct 2023 | 67 |
| Nov 2023 | 67 |
| Dec 2023 | 64 |
| Jan 2024 | 64 |
| Feb 2024 | 64 |
| Apr 2024 | 64 |
| May 2024 | 64 |
| Jun 2024 | 68 |
| Jul 2024 | 68 |
Janux Therapeutics other data
16.10%
-53.62%
of JANX is owned by hedge funds
23
-27
6.67M
-22.27M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 1397849 | 0 |
| Jun 2024 | 0 | 3822721 |
| Sep 2024 | 0 | 1082685 |
| Oct 2024 | 1200000 | 1698128 |
| Nov 2024 | 0 | 25000 |
| Dec 2024 | 0 | 40000 |
| Insider | Compensation |
|---|---|
Dr. David Alan Campbell (1960) Pres, Chief Executive Officer & Director | $585,810 |
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Best-Performing Stocks Of 2024
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy
BioAtla: A Buried ADC Concern Gets Some New Life In 2024
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
-
What's the price of Janux Therapeutics stock today?
One share of Janux Therapeutics stock can currently be purchased for approximately $24.69.
-
When is Janux Therapeutics's next earnings date?
Unfortunately, Janux Therapeutics's (JANX) next earnings date is currently unknown.
-
Does Janux Therapeutics pay dividends?
No, Janux Therapeutics does not pay dividends.
-
How much money does Janux Therapeutics make?
Janux Therapeutics has a market capitalization of 3.21B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.14% to 8.08M US dollars. Janux Therapeutics made a loss 58.29M US dollars in net income (profit) last year or -$0.3 on an earnings per share basis.
-
What is Janux Therapeutics's stock symbol?
Janux Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "JANX".
-
What is Janux Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Janux Therapeutics?
Shares of Janux Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Janux Therapeutics's key executives?
Janux Therapeutics's management team includes the following people:
- Dr. David Alan Campbell Pres, Chief Executive Officer & Director(age: 65, pay: $585,810)
-
How many employees does Janux Therapeutics have?
As Jul 2024, Janux Therapeutics employs 68 workers, which is 6% more then previous quarter.
-
When Janux Therapeutics went public?
Janux Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 11 Jun 2021.
-
What is Janux Therapeutics's official website?
The official website for Janux Therapeutics is januxrx.com.
-
Where are Janux Therapeutics's headquarters?
Janux Therapeutics is headquartered at 11099 North Torrey Pines Road, La Jolla, CA.
-
How can i contact Janux Therapeutics?
Janux Therapeutics's mailing address is 11099 North Torrey Pines Road, La Jolla, CA and company can be reached via phone at 858 750 4700.
-
What is Janux Therapeutics stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Janux Therapeutics in the last 12 months, the avarage price target is $70.25. The average price target represents a 184.52% change from the last price of $24.69.
Janux Therapeutics company profile:
Janux Therapeutics, Inc.
januxrx.comExchange:
NASDAQ
Full time employees:
76
Industry:
Biotechnology
Sector:
Healthcare
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
11099 North Torrey Pines Road
La Jolla, CA 92037
La Jolla, CA 92037
CIK: 0001817713
ISIN: US47103J1051
CUSIP: 47103J105
